Damian Szatkowski

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Sonja Zweegman, Bronno van der Holt, Ulf‐Henrik Mellqvist et al. · Blood · 2016 · 112 citations · Full text

Medicine, Hematology, Oncology +14

α-Melanocyte-Stimulating Hormone Modulates Nitric Oxide Production in Melanocytes1

Alison Graham, Philip Manning, Calum J. McNeil et al. · Journal of Investigative Dermatology · 2000 · 60 citations · Full text

Life Sciences, Cell Biology, Endocrinology +6

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

Jan Maciej Zaucha, Witold Prejzner, Sebastian Giebel et al. · Bone Marrow Transplantation · 2005 · 43 citations

Medicine, Hematology, Immunology +10

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Lene Kongsgaard Nielsen, Claudia A.M. Stege, Birgit I. Lissenberg‐Witte et al. · Haematologica · 2019 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, Fredrik Schjesvold, Bronno van der Holt et al. · Blood · 2018 · 11 citations

Medicine, Hematology, Pharmacotherapy +17